All In Biotech

NDA 200175 · Cosette

Tribenzor

Amlodipine Besylate, Hydrochlorothiazide, Olmesartan Medoxomil · Oral · Thiazide Diuretic

Last checked: Nov 20, 2026Latest source record: Oct 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jul 23, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

1,244

713 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Tribenzor as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus. ( 5.1 , 8.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Tribenzor as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).

What it is approved for

From the label in effect Jul 12, 2023.

Tribenzor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Tribenzor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is...

Mechanism: The active ingredients of Tribenzor target three separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume. For a more detailed description of the mechanisms of action for each individual...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • TRIBENZOR · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 25MG; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
  • TRIBENZOR · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 25MG; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
  • TRIBENZOR · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
  • TRIBENZOR · AMLODIPINE BESYLATE EQ 10MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
  • TRIBENZOR · AMLODIPINE BESYLATE EQ 5MG BASE; HYDROCHLOROTHIAZIDE 12.5MG; OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sprue-like enteropathy231
  • gastrooesophageal reflux disease141
  • acute kidney injury105
  • weight decreased105
  • diarrhoea104
  • dizziness104
  • constipation77
  • haemorrhoids76
  • chronic kidney disease72
  • nausea67
  • fatigue66
  • large intestine polyp60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
201131
201247
201372
201479
2015206
2016216
2017176
2018208
201992
202027
202115
202217
202313
202411
202512
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tribenzor (Olmesartan/Amlodipin/HCThiazid)

2024 spending

$1.5M

Beneficiaries

423

2,198 claims

Per beneficiary

$3,610

$14.19 per unit

View as table
YearSpending
2020$0
2021$0
2022$291,547
2023$1,757,491
2024$1,527,171

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,807 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.